AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25084263 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25084608 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam radiation therapy to the surgical bed, 40 Gy in 10 fractions, once daily over 2 weeks.
Number of subjects: 100
Study 25085007 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPP Network's integrated multi-disciplinary research approach
Number of subjects: 0
Study 25085119 — intervention group
Group type: EXPERIMENTAL
Intervention: UCPPS participants
Number of subjects: 1039
Study 25085119 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1039
Study 25085119 — intervention group
Group type: COMPARATOR
Intervention: Positive controls (NUAS criteria)
Number of subjects: 1039
Study 25085333 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric volume reduction with an endoscopic stapler
Number of subjects: 17
Study 25085385 — intervention group
Group type: EXPERIMENTAL
Intervention: CareWell in Hospital program
Number of subjects: 386
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic amniotic fluid in normal birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex in normal birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth season in low birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal body temperature in low birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment at the time of labor in low birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of pregnancy consultations in low birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age in low birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Apgar score in low birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant convulsions in low birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic amniotic fluid in low birth weight infants
Number of subjects: 792
Study 25085521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery in low birth weight infants
Number of subjects: 792
Study 25085632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (Sutent) - a VEGFR2/PDGFRβ/c-kit/FLT3/RET/CSF1R inhibitor
Number of subjects: 5
Study 25086446 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based psychological coping
Number of subjects: 97
Study 25086446 — intervention group
Group type: COMPARATOR
Intervention: Control for age, education, and time since diagnosis
Number of subjects: 97
Study 25086465 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib, dacarbazine, and capecitabine regimen (imatinib 300 mg daily on days 1-21, dacarbazine 250 mg/m2 daily on days 1-3, capecitabine 500 mg/m2 twice daily on days 1-14)
Number of subjects: 20
Study 25086465 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib, dacarbazine, and capecitabine regimen
Number of subjects: 20
Study 25086913 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (61.2%)
Number of subjects: 983
Study 25086913 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (18%)
Number of subjects: 983
Study 25087103 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartWare HVAD system
Number of subjects: 332
Study 25087889 — intervention group
Group type: EXPERIMENTAL
Intervention: LEFt clinical decision rule (scoring system based on left leg suspicion, edema, and trimester)
Number of subjects: 96
Study 25087889 — intervention group
Group type: EXPERIMENTAL
Intervention: LEFt clinical decision rule
Number of subjects: 96
Study 25090481 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline diabetic knowledge after five-day teaching program
Number of subjects: 79
Study 25090645 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03A-H5N1 vaccine (3.75μg hemagglutinin-antigen)
Number of subjects: 78
Study 25091095 — intervention group
Group type: EXPERIMENTAL
Intervention: Viance peripheral CTO crossing device
Number of subjects: 58
Study 25091263 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day on days 2-5, 9-12, 16-26 of each 28-day cycle plus gemcitabine 1000 mg/m(2) as an intravenous infusion over 30-min on days 1, 8, 15
Number of subjects: 30
Study 25091263 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus gemcitabine
Number of subjects: 30
Study 25091537 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam for inhalation solution (AZLI) 75 mg 3 times daily for 28 days
Number of subjects: 105
Study 25091619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 40 mg/m² on day one of a 21 day cycle
Number of subjects: 26
Study 25091629 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and/or resistance training programmes
Number of subjects: 112
Study 25092772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib monotherapy
Number of subjects: 0
Study 25092789 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater left ventricular dyssynchrony (measured by standard deviation of time to peak systolic strain, SD-TPS) in women
Number of subjects: 1392
Study 25092789 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater left ventricular dyssynchrony (measured by SD-TPS) in women
Number of subjects: 1392
Study 25092878 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Restitution Instability Index (R2I2)
Number of subjects: 60
Study 25092878 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak ECG Restitution Slope (PERS)
Number of subjects: 60
Study 25092878 — intervention group
Group type: EXPERIMENTAL
Intervention: R2I2≥1.03
Number of subjects: 60
Study 25092878 — intervention group
Group type: EXPERIMENTAL
Intervention: R2I2 and PERS positive
Number of subjects: 60
Study 25093475 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief pulse right unilateral electroconvulsive therapy (ECT)
Number of subjects: 0
Study 25093475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse right unilateral electroconvulsive therapy (ECT)
Number of subjects: 0
Study 25096860 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISm subjects
Number of subjects: 10192
Study 25096860 — intervention group
Group type: EXPERIMENTAL
Intervention: GWAS testing
Number of subjects: 10192
Study 25096860 — intervention group
Group type: EXPERIMENTAL
Intervention: K-means clustering
Number of subjects: 10192
Study 25097199 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial CD34(+) cell transplantation
Number of subjects: 33
Study 25097199 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 33
Study 25098184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (text message and voucher component)
Number of subjects: 2550
Study 25098184 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2550
Study 25098184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention
Number of subjects: 2550
Study 25098565 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 36
Study 25098565 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGBP
Number of subjects: 36
Study 25098701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy
Number of subjects: 210
Study 25098701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combination therapy
Number of subjects: 210
Study 25098701 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (monotherapy and combination)
Number of subjects: 210
Study 25098701 — intervention group
Group type: COMPARATOR
Intervention: Prior hypertension
Number of subjects: 210
Study 25099027 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE/sorafenib combination
Number of subjects: 192
Study 25100734 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (≥30 min, 3 times per week)
Number of subjects: 274
Study 25100734 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise (sedentary)
Number of subjects: 274
Study 25101571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol stent treatment
Number of subjects: 998
Study 25102193 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 12
Study 25102383 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative Illness Rating Scale-Geriatric (CIRS-G)
Number of subjects: 76
Study 25103305 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib treatment
Number of subjects: 23
Study 25103395 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP T1 (treponemal) assay
Number of subjects: 703
Study 25103395 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP T2 (non-treponemal) assay
Number of subjects: 703
Study 25103395 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP T2 assay for specimens with an RPR titre of 1:8 or greater
Number of subjects: 703
Study 25103395 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP assay in children with dual-positive serology
Number of subjects: 703
Study 25103848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 131
Study 25103848 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 131
Study 25103913 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET-MRI
Number of subjects: 20
Study 25103913 — intervention group
Group type: COMPARATOR
Intervention: FDG PET-CT
Number of subjects: 20
Study 25104514 — intervention group
Group type: EXPERIMENTAL
Intervention: iSVT
Number of subjects: 1167
Study 25104514 — intervention group
Group type: EXPERIMENTAL
Intervention: iD-DVT
Number of subjects: 1167
Study 25104514 — intervention group
Group type: EXPERIMENTAL
Intervention: iP-DVT
Number of subjects: 1167
Study 25104797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 22
Study 25104797 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 22
Study 25104797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled group of patients undergoing bariatric surgery
Number of subjects: 22
Study 25105369 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with O6BG/TMZ chemotherapy
Number of subjects: 7
Study 25105369 — intervention group
Group type: COMPARATOR
Intervention: Historical controls without gene therapy
Number of subjects: 7
Study 25105742 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 50
Study 25105826 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) parameters: LF > 298 ms
Number of subjects: 120
Study 25105826 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) parameters: LF/HF > 3.1
Number of subjects: 120
Study 25105826 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between LF and NRS
Number of subjects: 120
Study 25105826 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between LF/HF and NRS
Number of subjects: 120
Study 25105826 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HF and NRS
Number of subjects: 120
Study 25105850 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous noninvasive arterial pressure (CNAP) device
Number of subjects: 104
Study 25106049 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Acceptance Questionnaire (PAAQ)
Number of subjects: 418
Study 25106049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Acceptance subscale of PAAQ
Number of subjects: 418
Study 25106049 — intervention group
Group type: EXPERIMENTAL
Intervention: PAAQ (test-retest reliability)
Number of subjects: 418
Study 25106673 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (SM) - side-lying, high velocity, low amplitude, over a course of 6 weeks
Number of subjects: 80
Study 25106673 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (SM)
Number of subjects: 80
Study 25106676 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks weight loss intervention
Number of subjects: 192
Study 25107437 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular stenting
Number of subjects: 300
Study 25109929 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25110173 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate drying and wrapping of the baby
Number of subjects: 22243
Study 25110173 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed bathing practices
Number of subjects: 22243
Study 25110173 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care
Number of subjects: 22243
Study 25110173 — intervention group
Group type: EXPERIMENTAL
Intervention: General thermal care behaviours
Number of subjects: 22243
Study 25110632 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg single dose
Number of subjects: 312
Study 25110632 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg single dose
Number of subjects: 312
Study 25110632 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg two doses
Number of subjects: 312
Study 25110632 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg two doses
Number of subjects: 312
Study 25111234 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin treatment (median duration 4 days, range 2-7 days)
Number of subjects: 18
Study 25112732 — intervention group
Group type: EXPERIMENTAL
Intervention: LCN2 levels in sera of healthy volunteers subjected to bed rest
Number of subjects: 0
Study 25112732 — intervention group
Group type: EXPERIMENTAL
Intervention: OBs-Lcn2 (osteoblasts transfected with LCN2-expression-vector)
Number of subjects: 0
Study 25112732 — intervention group
Group type: EXPERIMENTAL
Intervention: OBs-Lcn2
Number of subjects: 0
Study 25112732 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned media from OBs-Lcn2 cultures or coculture with OBs-Lcn2
Number of subjects: 0
Study 25112732 — intervention group
Group type: COMPARATOR
Intervention: Recombinant LCN2 treatment
Number of subjects: 0
Study 25112957 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 5
Study 25112957 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 5
Study 25112957 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 5
Study 25112957 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 5
Study 25112957 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load monitoring
Number of subjects: 5
Study 25113510 — intervention group
Group type: EXPERIMENTAL
Intervention: Discovery Link AFinder
Number of subjects: 472
Study 25113510 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 472
Study 25113510 — intervention group
Group type: COMPARATOR
Intervention: Standard in-hospital monitoring
Number of subjects: 472
Study 25113573 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced stair-climbing test measuring mechanical efficiency (MEnet)
Number of subjects: 43
Study 25113573 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted MEnet for T2 and T1
Number of subjects: 43
Study 25113573 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-climbing test
Number of subjects: 43
Study 25113756 — intervention group
Group type: EXPERIMENTAL
Intervention: LCL161 (1,800 mg, oral, once weekly, tablet formulation)
Number of subjects: 53
Study 25113756 — intervention group
Group type: EXPERIMENTAL
Intervention: LCL161 (tablet formulation)
Number of subjects: 53
Study 25113756 — intervention group
Group type: EXPERIMENTAL
Intervention: LCL161 (1,800 mg)
Number of subjects: 53
Study 25113840 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel-calibre MRI
Number of subjects: 0
Study 25113840 — intervention group
Group type: COMPARATOR
Intervention: Traditional assessments of tumour volume
Number of subjects: 0
Study 25114140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV/r)
Number of subjects: 0
Study 25114140 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine
Number of subjects: 0
Study 25114584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-600 mg/day)
Number of subjects: 103
Study 25114718 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-HER2 agents
Number of subjects: 15
Study 25114916 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ASD during routine dental cleanings
Number of subjects: 44
Study 25114916 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological measures of distress in children with ASD
Number of subjects: 44
Study 25114916 — intervention group
Group type: COMPARATOR
Intervention: Behavioral distress in the typical group
Number of subjects: 44
Study 25114916 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral distress in the ASD group
Number of subjects: 44
Study 25114916 — intervention group
Group type: COMPARATOR
Intervention: Physiological distress in the typical group
Number of subjects: 44
Study 25114916 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological distress in the ASD group
Number of subjects: 44
Study 25115686 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (1 gm daily for 12 weeks)
Number of subjects: 40
Study 25115882 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended follow-up studies
Number of subjects: 0
Study 25115992 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 60
Study 25115992 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 60
Study 25116755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, GM-CSF-secreting breast tumor vaccine, and trastuzumab
Number of subjects: 20
Study 25116908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi meditation
Number of subjects: 0
Study 25116908 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25117135 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25117475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel/cisplatin (15/75 mg/m²)
Number of subjects: 25
Study 25117475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel/cisplatin (20/75 mg/m²)
Number of subjects: 25
Study 25117615 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 250 mg
Number of subjects: 27
Study 25117615 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 500 mg
Number of subjects: 27
Study 25117615 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg (1 h premeal)
Number of subjects: 27
Study 25117615 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1000 mg (2 h postmeal)
Number of subjects: 27
Study 25117615 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA)
Number of subjects: 27
Study 25119513 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation module
Number of subjects: 56
Study 25119513 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise module
Number of subjects: 56
Study 25119513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Coping module
Number of subjects: 56
Study 25119513 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-therapist working alliance and patient expectations of treatment benefit
Number of subjects: 56
Study 25119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in the PREDICT cohort
Number of subjects: 1675
Study 25119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in the original validation cohort
Number of subjects: 1675
Study 25119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in non-Caucasian patients
Number of subjects: 1675
Study 25119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in Caucasian patients
Number of subjects: 1675
Study 25119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-testing of stored samples from the original validation cohort after 5 years
Number of subjects: 1675
Study 25119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression score (GES) for obstructive CAD in the COMPASS study
Number of subjects: 1675
Study 25119856 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in cardiovascular medications
Number of subjects: 1675
Study 25122609 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC294640 (a SK2 specific inhibitor)
Number of subjects: 0
Study 25122609 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC294640
Number of subjects: 0
Study 25122609 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC294640 + ABT-737 (a Bcl-2 inhibitor)
Number of subjects: 0
Study 25122629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (PNE) with eccentric exercise (EccEx) and stretching, 1 session per week for 4-6 weeks
Number of subjects: 36
Study 25122629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (PNE) with eccentric exercise (EccEx) and stretching
Number of subjects: 36
Study 25122650 — intervention group
Group type: COMPARATOR
Intervention: Pica group (n = 72)
Number of subjects: 158
Study 25122650 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pica group (n = 86)
Number of subjects: 158
Study 25122663 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PL-saturated fatty acid
Number of subjects: 2448
Study 25122663 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenously synthesized PL ω6 fatty acids (20:3n-6)
Number of subjects: 2448
Study 25122663 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenously synthesized PL ω6 fatty acids (22:5n-6)
Number of subjects: 2448
Study 25122663 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ6-desaturase
Number of subjects: 2448
Study 25122663 — intervention group
Group type: EXPERIMENTAL
Intervention: PL-ω3 fatty acids (20:5n-3)
Number of subjects: 2448
Study 25122663 — intervention group
Group type: EXPERIMENTAL
Intervention: PL-ω3 fatty acids (22:5n-3)
Number of subjects: 2448